Quick Recap
Cardiovascular System, Protocol 11/12. Acute aortic syndrome-associated hypertensive emergency has special BP/HR targets and beta-blocker-first sequencing — covered here and cross-referenced to the dedicated Acute Aortic Syndromes protocol.
1. Definitions
Hypertensive crisis: generic term for severe BP elevation with potential for target organ damage (TOD) — encompasses both emergency and urgency.
Hypertensive urgency: severe BP elevation WITHOUT evidence of acute, ongoing TOD.
Hypertensive emergency: severe BP elevation WITH evidence of acute, ongoing TOD (heart, vasculature, kidneys, eyes, brain).
Hypertensive encephalopathy: irritability, headache, mental status changes from significant/rapid BP elevation.
Accelerated malignant hypertension: papilledema and/or acute retinal hemorrhages/exudates on fundoscopy.
Critical concept: no absolute BP number defines these entities — the threshold for TOD varies with the chronicity and rapidity of the rise. A patient with long-standing poorly controlled hypertension may tolerate BP >230/120 without acute TOD, while a young previously normotensive patient with acute glomerulonephritis may become encephalopathic at much lower pressures. ~1% of hypertensive patients will experience a hypertensive emergency in their lifetime — severe BP elevation alone is common, true emergencies are comparatively rare, making the emergency-vs-urgency distinction the central clinical task.
2. Pathophysiology
Abrupt, severe BP rise overwhelms autoregulatory capacity in vascular beds (cerebral, renal, coronary, retinal) -> endothelial injury, fibrinoid necrosis of arterioles, and impaired autoregulation -> the specific organ manifestation depends on which vascular bed is most vulnerable in that patient (cerebral autoregulation failure -> encephalopathy; renal microvascular injury -> AKI; coronary demand mismatch -> ischemia; aortic wall shear stress -> dissection propagation).
3. Immediate Stabilization / General Approach
Rapid, truncated history and exam with two goals: (1) identify patient characteristics placing them at risk for a true emergency, (2) actively search for signs/symptoms of TOD. If TOD is found, treat immediately, preferably in an ICU setting. If no TOD is found (urgency), aggressive rapid IV BP lowering is NOT indicated — oral agents with a longer time-to-goal are appropriate, and unnecessary aggressive lowering risks organ hypoperfusion.
General principles for confirmed emergency:
- Use rapid-onset, short-half-life PARENTERAL agents, ideally under intra-arterial BP monitoring in an ICU — allows precise titration and immediate cessation if overshooting
- Do NOT use oral/sublingual agents as initial treatment — variable absorption, slower onset, longer half-life risk unpredictable/excessive BP drops
- General goal: reduce MAP by no more than ~10-20% in the first hour, then a further gradual reduction over the next 23 hours to ~160/100-110 if tolerated (standard teaching for most hypertensive emergencies) — exceptions with their own specific, more aggressive or more conservative targets apply for ischemic stroke, aortic dissection, and other syndrome-specific scenarios (see Section 5 and cross-referenced protocols)
- Overly aggressive correction risks organ hypoperfusion (watershed cerebral infarction, coronary ischemia, ATN) — the balance between stopping TOD progression and avoiding overcorrection is the central management tension
Checklist:
4. Focused History / Precipitant Identification
Medication non-adherence to home antihypertensives, sympathomimetic/stimulant use (cocaine, amphetamines), MAOI + tyramine interaction, abrupt clonidine/beta-blocker withdrawal, pregnancy (preeclampsia/eclampsia — see Obstetric protocols), known renal disease (glomerulonephritis, renal artery stenosis — including transplant renal artery stenosis in transplant recipients), pheochromocytoma symptoms (episodic headache/palpitations/diaphoresis), autonomic dysreflexia (spinal cord injury above T6), known aortic aneurysm/dissection history, chest/back/abdominal pain pattern ("think Aorta"), visual symptoms, focal neurologic symptoms.
5. Syndrome-Specific Management (the core of this protocol)
Aortic Dissection / Acute Aortic Syndrome (see also dedicated Acute Aortic Syndromes protocol)
- Beta-blocker FIRST, before any vasodilator — reduces shear stress (dP/dt) on the aortic wall; starting a vasodilator first risks reflex tachycardia, which INCREASES dP/dt and can propagate the dissection
- Target: SBP <120 mmHg and HR <60-70 bpm, titrated as low as possible without compromising end-organ perfusion
- Esmolol (bolus 250-500 mcg/kg, infusion 50-100 mcg/kg/min, short half-life allows rapid titration) or labetalol (bolus 20mg over 2min, then 20-80mg q10min to max 300mg, then infusion 0.5-2mg/min) as first-line
- If SBP remains elevated despite adequate beta-blockade, ADD a vasodilator: nicardipine (5mg/h, titrate by 2.5mg/h q5-15min, max 15mg/h), clevidipine (1-2mg/h, up to 16-32mg/h), or sodium nitroprusside (0.3-0.5 mcg/kg/min, titrate, max ~2-10 mcg/kg/min depending on source — watch thiocyanate toxicity)
- Opioids for pain control are an important adjunct to help achieve BP goals (pain itself drives sympathetic tone/BP)
Hypertensive Encephalopathy
- Goal: reduce MAP by ~20-25% in the first hour (do not normalize BP acutely — risk of watershed cerebral ischemia given impaired autoregulation)
- Nitroprusside historically favored given rapid onset/offset, though it modestly increases ICP — the accompanying fall in SVR is considered to offset this effect, so it remains a reasonable choice; nicardipine or labetalol are also appropriate
Ischemic Stroke
- Permissive hypertension is generally favored (see dedicated Stroke protocol for specific numeric thresholds, which differ depending on thrombolysis/thrombectomy candidacy) — aggressive BP lowering can worsen penumbral perfusion; defer to the Stroke protocol's specific targets rather than applying the generic hypertensive emergency approach here.
Intracerebral/Subarachnoid Hemorrhage
- See dedicated Intracranial Hemorrhage/SAH protocols for specific SBP targets (generally more aggressive lowering than ischemic stroke, but still individualized) — do not apply the generic hypertensive emergency target here either.
Acute Pulmonary Edema / ADHF with Hypertensive Crisis
- IV nitroglycerin first-line (balanced arterial/venous vasodilator at higher doses; primarily venodilatory at low doses — titrate aggressively) or nitroprusside (balanced dilation at all doses)
- Avoid non-dihydropyridine CCBs and standard beta-blockers acutely (myocardial depressant effect) — see Acute Heart Failure protocol for full detail
Acute Coronary Syndrome with Hypertension
- Nitroglycerin first-line (coronary vasodilation + preload reduction); beta-blockers as tolerated per ACS protocol (avoid in cardiogenic shock)
Acute Kidney Injury / Renal Crisis (e.g., scleroderma renal crisis)
- Fenoldopam (dopamine-1 receptor agonist, selectively increases renal blood flow while lowering BP — theoretical renal-protective advantage) or enalaprilat (the only available IV ACE inhibitor; particularly useful adjunct in scleroderma renal crisis specifically, though response is unpredictable and depends on plasma renin activity/volume status)
Catecholamine Excess States (Pheochromocytoma, Cocaine/Stimulant Toxicity, MAOI-Tyramine Interaction, Clonidine Withdrawal)
- Avoid unopposed beta-blockade — blocking beta-receptors while leaving alpha-mediated vasoconstriction unopposed can cause paradoxical severe hypertension (analogous to the WPW/AV-nodal-blocker principle in the Arrhythmias protocol)
- Phentolamine (alpha-blocker) or benzodiazepines (particularly for cocaine/stimulant-associated hypertension, addressing the sympathetic surge directly) are preferred; nitroprusside/nicardipine are reasonable non-selective alternatives
- Clonidine withdrawal: reinstitute clonidine or use an alternative agent; avoid beta-blockade for the same unopposed-alpha reasoning
Autonomic Dysreflexia (spinal cord injury above T6)
- Identify and remove the triggering stimulus FIRST (bladder distension, fecal impaction, pressure sore, ingrown toenail, etc.) — often resolves the crisis without needing aggressive pharmacotherapy; nifedipine or nitrates as needed if BP remains elevated after trigger removal.
Hypertension in Pregnancy (preeclampsia/eclampsia)
- Labetalol or hydralazine are the classically preferred agents (extensive safety data in pregnancy); avoid ACE inhibitors/ARBs and nitroprusside (fetal cyanide risk with prolonged use) — see dedicated Obstetric ICU protocols for full eclampsia/HELLP management.
6. Parenteral Agent Reference Table
Drug | Dose | Onset/Duration | Key toxicity | Best-suited scenario |
Sodium nitroprusside | 0.25-0.5 mcg/kg/min initial, titrate to max ~8-10 mcg/kg/min | Onset seconds; offset 2-3 min | Cyanide/thiocyanate toxicity (esp. renal/hepatic impairment, prolonged use >24-48h, or high-dose infusions >10 min) | Most hypertensive emergencies; increases ICP slightly but offset by SVR fall, still used in encephalopathy |
Labetalol | Bolus 20mg, then 20-80mg q10min (max 300mg) OR infusion 0.5-2mg/min | Onset 5-10 min; duration 3-6h | Bradycardia, heart block, bronchospasm, HF exacerbation | Most emergencies EXCEPT CHF/reactive airway disease/heart block; preferred in pregnancy and aortic dissection |
Nicardipine | 0.5-2.5 mcg/kg/min (varies by source/indication) | Onset 5-15 min; duration 4-6h | Reflex tachycardia, headache, flushing, peripheral edema | ADHF (arterial-predominant), aortic dissection (after beta-blockade) |
Nitroglycerin | 5-200 mcg/min | Onset 2-5 min; duration 5-15 min | Headache, tachyphylaxis, hypotension, methemoglobinemia | Cardiac ischemia, ADHF with pulmonary edema; avoid with PDE5 inhibitors/volume depletion |
Hydralazine | 10-20mg q30min | Onset 10-30 min; duration 2-4h | Reflex tachycardia, unpredictable response | Pregnancy; use with beta-blocker if CAD/dissection given reflex sympathetic stimulation; avoid in elevated ICP |
Enalaprilat | 1.25mg initial, then 1.25-5mg q6h | Onset 15-30 min; duration 6-12h | Hypotension, renal failure, hyperkalemia, angioedema | Adjunct in CHF, scleroderma renal crisis; response unpredictable (renin/volume-dependent) |
Esmolol | Bolus 250-500 mcg/kg, infusion 50-100 mcg/kg/min | Very rapid onset/offset | Bradycardia, bronchospasm | Aortic dissection (short half-life allows rapid titration) |
Fenoldopam | 0.1-1.6 mcg/kg/min | Rapid onset | Reflex tachycardia, hypokalemia | Renal impairment/AKI-associated emergencies (selective renal vasodilation) |
Clevidipine | 1-2mg/h, up to 16-32mg/h | Rapid onset/offset | Hypertriglyceridemia, AF, fever | Aortic dissection adjunct, general ICU titration |
7. Investigations
Focused on identifying TOD and the underlying etiology: ECG/troponin (cardiac ischemia), CXR (pulmonary edema), renal function/urinalysis (AKI, glomerulonephritis), fundoscopy (papilledema/hemorrhages), head CT if encephalopathy/neurologic deficit, CT angiography chest if dissection suspected ("think Aorta"), pregnancy test in women of childbearing age, toxicology screen if stimulant use suspected, catecholamine/metanephrine testing if pheochromocytoma suspected (not urgent, can follow acute stabilization).
8. Consultation Matrix
Consultation | Trigger | Timing |
Cardiothoracic/Vascular Surgery | Aortic dissection | Immediate |
Nephrology | Renal crisis/AKI-associated emergency | Urgent |
Neurology | Encephalopathy, stroke, ICH/SAH | Immediate |
Obstetrics | Pregnancy-associated hypertensive emergency | Immediate |
Endocrinology | Suspected pheochromocytoma | Once stabilized |
9. Monitoring Framework
Intra-arterial BP monitoring strongly preferred during active titration of parenteral agents; continuous cardiac monitoring; serial neurologic exams if encephalopathy/stroke/ICH; serial renal function; watch for overcorrection signs (altered mentation, oliguria, ischemic chest pain) as much as under-treatment.
10. Complications
Overcorrection-induced organ hypoperfusion (watershed cerebral infarct, coronary ischemia, ATN), drug-specific toxicity (nitroprusside cyanide/thiocyanate, hydralazine drug-induced lupus, labetalol bronchospasm/heart block), paradoxical hypertension from unopposed alpha-agonism if beta-blocker given in catecholamine excess states, dissection propagation if vasodilator given before beta-blockade. Prevention: syndrome-specific target selection (not generic), beta-blocker-first sequencing in dissection, avoiding unopposed beta-blockade in catecholamine excess. Rescue: stop/reduce infusion for overcorrection, add beta-blocker if vasodilator given first in dissection and reflex tachycardia develops.
11. Escalation & De-escalation
Escalate: BP not responding to first-line agent at max dose -> add second agent per syndrome-specific pathway (Section 5).
De-escalate: BP at goal, TOD stabilizing/improving -> transition from IV to oral antihypertensive therapy over 24-48h as tolerated, address underlying precipitant (medication adherence counselling, pheochromocytoma workup, etc.).
12. ICU Discharge Criteria
BP controlled on transitioning oral regimen, TOD stabilized or improving (renal function, neurologic status, cardiac markers), underlying precipitant identified/addressed, outpatient follow-up and medication adherence plan established.
13. Documentation & Medicolegal Checklist
14. Key Guidelines
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71(6):e13-e115.
15. Controversies
The precise percentage/rate of MAP reduction in the first hour is guided more by long-standing expert consensus (Calhoun & Oparil 1990, Gifford 1991) than by contemporary RCT evidence, and the "10-20% in the first hour" teaching, while widely followed, is not rigidly evidence-based for every etiology equally — syndrome-specific protocols (stroke, ICH, dissection) have since developed more specific, better-supported targets that should supersede the generic teaching where they apply. Nitroprusside's cyanide/thiocyanate toxicity risk profile makes many clinicians favor nicardipine or clevidipine as first-line where available, despite nitroprusside's traditional "preferred agent" status in older references.
16. References
- Juang P. Approach to Hypertensive Emergencies. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 24).
- Vasodilator/afterload reduction tables. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 23, ADHF chapter).
- Pharmacologic Therapy for Acute Aortic Syndromes table. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 22).
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA hypertension guideline. Hypertension. 2018;71(6):e13-e115.
- Calhoun DA, Oparil S. Treatment of hypertensive crisis. N Engl J Med. 1990;323(17):1177-1183.
See also: Acute Aortic Syndromes, Acute Heart Failure, Acute Coronary Syndrome (Cardiovascular System); Stroke, Intracranial Hemorrhage, Subarachnoid Hemorrhage (Neurology System) for syndrome-specific BP targets.